High Throughput Screening of Infectious Virus Entry in Mammalian Cells
News Jun 07, 2007
Researchers at the Institute of Molecular Systems Biology (IMSB), Swiss Federal Institute of Technology (ETH), Zurich, Switzerland, are using two customized Tecan Freedom EVO® 200 liquid handling workstations as part of a study to identify the specific sets of host genes that viruses depend on to infect cells.
The large-scale, genome-wide study aims to individually silence 7,000 mammalian genes using RNA interference (RNAi), and measure how each silencing affects the abilities of 11 different viruses, including influenza, herpes and SV40, to infect mammalian hosts.
The automated set-up is critical to the project, as analyzing the effects of silencing 7,000 genes on one virus requires 207 384-well plates and takes about two weeks to complete.
One Freedom EVO workstation is equipped with a Te-MO™ 384-channel pipetting head to perform all the transfection and infection assays. The second workstation has a Te-Stack™ stacker module and two fully integrated Cell-Works microscopes for automated quantification of the proportion of virus-transfected cells.
Dr Pelkmans, assistant professor at the IMSB, explained: “The project is providing valuable information about how viruses hijack endocytic pathways for host entry and, potentially, could lead to the development of novel anti-viral therapies targeted against host cellular genes instead of viral components. We have already seen some very exciting results.”
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Potential Barcode Identified for a Form of Alcoholic Liver DiseaseNews
NIAAA-supported researchers have discovered that extracellular vesicles released by liver cells in a mouse model of alcoholic steatohepatitis contain a miRNA signature detectable in the blood.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018